We promote the health and safety of the population through regulatory activities. And involvement in the pharmaceutical services sector development.
Fimea supervises and develops the pharmaceutical sector and promotes the rational use of pharmaceuticals in order to improve the health of the population. Fimea is a national regulatory and licensing authority in the pharmaceutical sector, operating under the Ministry of Social Affairs and Health.
Our vision
The effectiveness, safety, availability and sensible use of medicines is world-class in Finland.

Our values
- Effectiveness
- Reliability
- Innovation and Development
- Respect for collaboration and people
Fimea employees on average

- Have a university degree: >85%
- >50% special competencies in medicine or pharmacy
- Most common titles: SENIOR MEDICAL OFFICER, SENIOR RESEARCHER, COORDINATOR FOR MARKETING AUTHORISATIONS
- Are middle aged: 47 years
- There is 250 of us.
- Men: 28%, Women: 72%
- We participate in 85 international working groups, committees and organisations.
- Our experts engage actively in international collaboration in the working groups and duties of regulatory networks.
We are part of the European medicines regulatory network and promote the active international co-operation.

Emphasising **biological medicines**, **medicines that are significant from a public health perspective**, **personalised pharmacotherapy** and **generic medicines**.

- Actively seeking international tasks related to marketing authorisation and monitoring.
- Offering guidance to promising innovative drugs by providing structured special advisory within the EU Innovation Network.
- Participating actively as a partner in the Health Technology Assessment (EUnetHTA) Network.
- Participating also the European Surveillance of Veterinary Antimicrobial Consumption ESVAC project.
Fimea’s key figures

Fimea’s annually operating expenditure is about EUR 25 million, EUR 21.5 million being covered by revenue from chargeable services. The remainder of the expenditure consists of budget-funded operations.

FINANCE

State budget 15%

Fees 85%

ORGANISATION

DIRECTOR GENERAL

DIRECTOR

Supervision and licences process

- Inspectorate
- Quality surveillance unit
- Supervision control and development unit

DIRECTOR

Assessment of medicinal products process

- Regulatory processes unit
- Clinico-pharmacological unit
- Pharmacological unit
- Pharmacovigilance unit
- Veterinary medicines unit

DIRECTOR

Assessment of pharmacotherapies process

- Administrative services
- Financial administration
- Information resources management

DIRECTOR

Internal services

- Communications
- Strategic development
- Internal audit
- Information services
- Executive secretarial services
Approximately **28,000** marketing authorisation cases for medicines are processed at Fimea annually.

There are about **10,000** valid marketing authorisations for medicines in Finland, **1,000** of them are for veterinary medicines.

Each year, about **25,000** decisions on special permissions for compassionate use are made.

The volume of laboratory services is approximately **1,000** per year.

About **170** inspections to pharmacies, pharmaceutical plants, laboratories and pharmaceutical wholesale dealers are made annually.

About **200** cases of product defects are processed annually.

Import and export authorisation for narcotic drugs are made annually approximately **1,500**.

Licenses and other decisions for the pharmaceutical actors are granted almost **2,300** annually.
We operate digitally and in multiple sites.

Our personnel works at **Kuopio**, **Helsinki**, **Tampere**, **Turku** and **Oulu**. You can reach us with the same contact details.